Checkpoint inhibitors (CIs) are among the hottest tickets in biopharma, with a handful of deals this year showing that no respectable oncology pipeline can be without one. Combined with traditional chemotherapy and radiation treatment, CIs made a big first impression in metastatic melanoma, thanks to the early success of Yervoy (ipilimumab, Bristol-Myers Squibb Co.).